JP2016508155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508155A5 JP2016508155A5 JP2015552096A JP2015552096A JP2016508155A5 JP 2016508155 A5 JP2016508155 A5 JP 2016508155A5 JP 2015552096 A JP2015552096 A JP 2015552096A JP 2015552096 A JP2015552096 A JP 2015552096A JP 2016508155 A5 JP2016508155 A5 JP 2016508155A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solid solution
- solution pharmaceutical
- weight
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 239000006104 solid solution Substances 0.000 claims 20
- 208000002193 Pain Diseases 0.000 claims 8
- 239000007788 liquid Substances 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- 150000003626 triacylglycerols Chemical class 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 239000003381 stabilizer Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000003472 neutralizing Effects 0.000 claims 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims 3
- 230000001225 therapeutic Effects 0.000 claims 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18β-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims 2
- ZIUSSTSXXLLKKK-HWUZOJPISA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(\O)=C/C(=O)/C=C/C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-HWUZOJPISA-N 0.000 claims 2
- -1 PEG500 Polymers 0.000 claims 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- 229920001451 Polypropylene glycol Polymers 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims 2
- 235000003441 saturated fatty acids Nutrition 0.000 claims 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3S,3aR,6R,6aR)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (R)-3,4-Dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2H-1-benzopyran-6-ol Chemical compound OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims 1
- DMCMOFCRZHRTKH-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethanol Chemical compound CCOCCOCCO.CCOCCOCCO DMCMOFCRZHRTKH-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940033495 ANTIMALARIALS Drugs 0.000 claims 1
- 208000005298 Acute Pain Diseases 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 229940109262 Curcumin Drugs 0.000 claims 1
- 229940073144 Glycyrrhetinic acid Drugs 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 206010019233 Headache Diseases 0.000 claims 1
- 229960003105 Metformin Drugs 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 229940053207 Niacin Drugs 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 108010044210 PPAR-beta Proteins 0.000 claims 1
- 229940116369 Pancreatic lipase Drugs 0.000 claims 1
- 102000019280 Pancreatic lipase Human genes 0.000 claims 1
- 108050006759 Pancreatic lipase Proteins 0.000 claims 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 claims 1
- 229920002596 Polyethylene Glycol 900 Polymers 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000078 anti-malarial Effects 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- WRZXKWFJEFFURH-UHFFFAOYSA-N dodecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WRZXKWFJEFFURH-UHFFFAOYSA-N 0.000 claims 1
- 229960003720 enoxolone Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 230000002969 morbid Effects 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 102000006255 nuclear receptors Human genes 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 102000037170 ryanodine receptor (TC 1.A.3.1) family Human genes 0.000 claims 1
- 108091006220 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 230000001975 sympathomimetic Effects 0.000 claims 1
- 239000011731 tocotrienol Substances 0.000 claims 1
- 229930003802 tocotrienols Natural products 0.000 claims 1
- 235000019148 tocotrienols Nutrition 0.000 claims 1
Claims (20)
- 固溶体医薬組成物であって、
a)約0.1重量%〜約40重量%の1種以上の治療用化合物;
b)少なくとも35重量%の1種以上の室温の固体脂質であって、1種以上のトリグリセリドを含む室温の固体脂質;および
c)約1重量%〜約50重量%の1種以上の安定化剤;
を含み、
前記固溶体医薬組成物が約15℃以下の温度において固体であり、かつ25℃以上の融点を有するるように製剤化されている、
前記固溶体医薬組成物。 - 前記1種以上の治療用化合物が、非ステロイド性抗炎症薬(NSAID)、PPARα作動薬、PPARβ/δ作動薬、PPARγ作動薬、グリタザール、リアノジン受容体拮抗薬、核内受容体結合剤、アンジオテンシンII受容体拮抗薬、ACE阻害剤、ホスホジエステラーゼ阻害剤、フィブラート、スタチン、トコトリエノール、ナイアシン、胆汁酸金属イオン封鎖剤(樹脂)、コレステロール吸収阻害剤、膵臓リパーゼ阻害剤、交感神経作用アミン、抗癌剤、メトホルミン、クルクミン、グリチルレチン酸、6−ショウガオール、抗生物質、抗蠕虫薬もしくは抗マラリア薬またはこれらの任意の組合わせを含む、請求項1の固溶体医薬組成物。
- 前記1種以上の治療用化合物が、約0.1重量%〜約35重量%、約1重量%〜約30重量%、約1重量%〜約25重量%、約1重量%〜約20重量%、約1重量%〜約15重量%、または約1重量%〜約10重量%の量で存在する、請求項1または2の固溶体医薬組成物。
- 前記1種以上のトリグリセリドが、C 12 〜C 24 の炭素長さの1つの飽和脂肪酸もしくは不飽和脂肪酸を有するトリグリセリド、それぞれがC 12 〜C 24 の炭素長さの2つの飽和脂肪酸もしくは不飽和脂肪酸を有するトリグリセリド、または、それぞれがC 12 〜C 24 の炭素長さの3つ飽和脂肪酸もしくは不飽和脂肪酸を有するトリグリセリドを含む、請求項1〜3のいずれか1項の固溶体医薬組成物。
- 前記1種以上のトリグリセリドが、約41℃〜約45℃の融点を有する飽和C10〜C18トリグリセリドの混合物を含む、請求項1〜4のいずれか1項の固溶体医薬組成物。
- 前記1種以上の室温の固体脂質が少なくとも40重量%、少なくとも45重量%、少なくとも50重量%、少なくとも55重量%、または少なくとも60重量%の量で存在する、請求項1〜5のいずれか1項の固溶体医薬組成物。
- 前記1種以上の室温の固体脂質が約35重量%〜約95重量%、約40重量%〜約95重量%、約45重量%〜約95重量%、または約50重量%〜約95重量%の量で存在する、請求項1〜5のいずれか1項の固溶体医薬組成物。
- 前記1種以上の安定化剤は、液体グリコールポリマー、一価アルコール、イソソルビドジメチルエーテル、またはジエチレングリコールモノエチルエーテル(2−(2−エトキシエトキシ)エタノール)を含む、請求項1〜7のいずれか1項の固溶体医薬組成物。
- 前記液体グリコールポリマーが、液体ポリエチレングリコール(PEG)ポリマーおよび/または液体ポリプロピレングリコール(PPG)ポリマーである、請求項8の固溶体医薬組成物。
- 前記液体PEGポリマーが、約1,000g/モル以下である、請求項10の固溶体医薬組成物。
- 前記液体PEGポリマーが、PEG100、PEG200、PEG300、PEG400、PEG500、PEG600、PEG700、PEG800、PEG900、PEG1000またはこれらの任意の組合せを含む、請求項9または10の固溶体医薬組成物。
- 前記1種以上の安定化剤が、約1重量%〜約20重量%の量で存在する、請求項1〜11のいずれか1項の固溶体医薬組成物。
- 前記1種以上の安定化剤が、約40重量%未満または約35重量%未満の量で存在する、請求項1〜11のいずれか1項の固溶体医薬組成物。
- 約0.1重量%〜約20重量%の1種以上の中和剤をさらに含む、請求項1〜13のいずれか1項の固溶体医薬組成物。
- 前記1種以上の中和剤が、1種以上の脂肪酸、酢酸ナトリウム、またはトリエタノールアミンを含む、請求項14の固溶体医薬組成物。
- 前記1種以上の中和剤が、約0.1重量%〜約15重量%、約1重量%〜約10重量%、または約1重量%〜約5重量%の量で存在する、請求項14または15の固溶体医薬組成物。
- 激痛状態の治療における使用のための請求項1〜16のいずれか1項の固溶体医薬組成物。
- 前記激痛状態が、急性痛、亜急性痛、または慢性痛である、請求項17の使用。
- 前記激痛状態が、侵害受容性疼痛、病的疼痛、関連痛、頭痛、または片頭痛である、前記請求項17の使用。
- 請求項1〜16のいずれか1項の固溶体医薬組成物の製造。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361752356P | 2013-01-14 | 2013-01-14 | |
US61/752,356 | 2013-01-14 | ||
US201361752309P | 2013-02-04 | 2013-02-04 | |
US61/752,309 | 2013-02-04 | ||
PCT/EP2014/050638 WO2014108574A1 (en) | 2013-01-14 | 2014-01-14 | Solid solution compositions and use in severe pain |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016508155A JP2016508155A (ja) | 2016-03-17 |
JP2016508155A5 true JP2016508155A5 (ja) | 2017-02-16 |
JP6378694B2 JP6378694B2 (ja) | 2018-08-22 |
Family
ID=50030251
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015552094A Active JP6505607B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および心血管疾患における使用 |
JP2015552095A Active JP6389190B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および慢性炎症における使用 |
JP2015552096A Active JP6378694B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および激痛における使用 |
JP2019061720A Pending JP2019116498A (ja) | 2013-01-14 | 2019-03-27 | 固溶体組成物および心血管疾患における使用 |
JP2021139210A Active JP7250865B2 (ja) | 2013-01-14 | 2021-08-27 | 固溶体組成物および心血管疾患における使用 |
JP2023045431A Pending JP2023078365A (ja) | 2013-01-14 | 2023-03-22 | 固溶体組成物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015552094A Active JP6505607B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および心血管疾患における使用 |
JP2015552095A Active JP6389190B2 (ja) | 2013-01-14 | 2014-01-14 | 固溶体組成物および慢性炎症における使用 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019061720A Pending JP2019116498A (ja) | 2013-01-14 | 2019-03-27 | 固溶体組成物および心血管疾患における使用 |
JP2021139210A Active JP7250865B2 (ja) | 2013-01-14 | 2021-08-27 | 固溶体組成物および心血管疾患における使用 |
JP2023045431A Pending JP2023078365A (ja) | 2013-01-14 | 2023-03-22 | 固溶体組成物 |
Country Status (16)
Country | Link |
---|---|
EP (6) | EP3578172B1 (ja) |
JP (6) | JP6505607B2 (ja) |
KR (6) | KR20230017914A (ja) |
CN (4) | CN105007947B (ja) |
AU (4) | AU2014204737B2 (ja) |
BR (3) | BR112015015891B1 (ja) |
CA (3) | CA2897884C (ja) |
ES (4) | ES2763352T3 (ja) |
HK (3) | HK1216004A1 (ja) |
IL (5) | IL282123B (ja) |
MX (3) | MX2015009105A (ja) |
NZ (1) | NZ709486A (ja) |
RU (3) | RU2674982C2 (ja) |
SG (4) | SG11201505249VA (ja) |
WO (3) | WO2014108573A1 (ja) |
ZA (3) | ZA201505002B (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
ES2763352T3 (es) * | 2013-01-14 | 2020-05-28 | Infirst Healthcare Ltd | Composiciones de solución sólida y uso en inflamación crónica |
PL3331568T3 (pl) * | 2015-08-07 | 2022-02-28 | Infirst Healthcare Limited | Kompozycje stałego roztworu dla nlpz |
US10307388B2 (en) * | 2016-12-29 | 2019-06-04 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and methods for diagnosis and treatment of inflammation |
AU2018354090A1 (en) | 2017-10-23 | 2020-03-12 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
JP7492459B2 (ja) * | 2018-05-16 | 2024-05-29 | エピトラッカー インコーポレイテッド | 加齢に関連する状態の診断及び治療のための組成物及び方法 |
EP3796976A4 (en) | 2018-05-23 | 2022-03-30 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO LONGEVITY AND QUALITY OF AGING |
CN108653273A (zh) * | 2018-07-13 | 2018-10-16 | 昆明医科大学第附属医院 | 青蒿素类化合物作为制备治疗贝赫切特病药物的应用 |
CN110251549B (zh) * | 2019-06-24 | 2021-12-03 | 浙江省肿瘤医院 | 淫羊藿总黄酮提取物在制备防治桥本甲状腺炎的药物中的应用 |
JP2022538872A (ja) * | 2019-06-28 | 2022-09-06 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 徐放脂質組成物及びその製造方法 |
CN113727708A (zh) * | 2019-07-21 | 2021-11-30 | Scf制药股份有限公司 | 具有多不饱和脂肪酸甘油单酯的大麻素组合物、其方法和用途 |
US20230057782A1 (en) * | 2020-02-03 | 2023-02-23 | Curemast, Inc. | Compositions and methods of use thereof for treatment of mastitis |
RU2752764C1 (ru) * | 2020-12-14 | 2021-08-03 | Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI") | Фармацевтическая композиция, обладающая противовоспалительным действием |
CN114601843A (zh) * | 2022-03-22 | 2022-06-10 | 重庆医科大学附属第一医院 | 淫羊藿苷在制备治疗自身免疫性葡萄膜炎药物中的用途 |
GB202208911D0 (en) * | 2022-06-17 | 2022-08-10 | Ravan Bio Limtied | Treatments |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
US5143934A (en) * | 1990-11-21 | 1992-09-01 | A/S Dumex (Dumex Ltd.) | Method and composition for controlled delivery of biologically active agents |
GB9613858D0 (en) * | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
EP0999826B1 (en) * | 1997-07-29 | 2004-05-06 | PHARMACIA & UPJOHN COMPANY | Self-emulsifying formulation for lipophilic compounds |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
GB2331458B (en) * | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
KR20020011985A (ko) * | 1999-05-07 | 2002-02-09 | 파르마솔 게엠베하 | 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법 |
TR200103188T2 (tr) * | 1999-05-07 | 2002-04-22 | Pharmasol Gmbh | Sıvı ve katı lipit karışımları temelli lipid parçacıklar. |
CN1173695C (zh) * | 1999-06-14 | 2004-11-03 | 科斯默股份公司 | 控制释放与掩蔽味道的口服药物组合物 |
IL148685A0 (en) * | 1999-09-21 | 2002-09-12 | Rtp Pharma Inc | Surface modified particulate compositions of biologically active substances |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US20060034937A1 (en) * | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
FR2805761B1 (fr) * | 2000-03-02 | 2002-08-30 | Mainelab | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
US6455067B1 (en) * | 2000-05-24 | 2002-09-24 | Sang-A Pharmaceutical Co., Ltd. | Transdermal patch for nonsteroidal antiinflammatory drug(s) |
JP2002284705A (ja) * | 2001-01-19 | 2002-10-03 | Shiseido Co Ltd | 刺激緩和剤 |
US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
WO2005009436A1 (en) * | 2003-07-31 | 2005-02-03 | Pharmacia & Upjohn Company Llc | Dispersible formulation of an anti-inflammatory agent |
EP1680091B1 (en) * | 2003-10-10 | 2017-05-31 | Veloxis Pharmaceuticals A/S | A solid dosage form comprising a fibrate |
AU2004291084A1 (en) * | 2003-11-13 | 2005-06-02 | Combinatorx, Incorporated | Methods and reagents for the treatment of inflammatory disorders |
EP1694305B1 (en) * | 2003-12-01 | 2019-10-16 | Recordati Ireland Limited | Pharmaceutical compositions comprising lercanidipine |
EP1750717B1 (en) * | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
BRPI0509148B8 (pt) * | 2004-03-22 | 2021-05-25 | Abbott Products Gmbh | composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina contendo tensoativos, seus usos e respectivos processos de fabricação |
CN101065115A (zh) * | 2004-11-24 | 2007-10-31 | 默克公司 | 取代酰胺的液体和半固体口服药物制剂 |
US20060138059A1 (en) | 2004-12-28 | 2006-06-29 | Vair Larry L Jr | Corona-treated polypropylene liquid filtration media |
EA012882B1 (ru) * | 2005-04-28 | 2009-12-30 | ДСМ АйПи ЭССЕТС Б.В. | Фармацевтические лекарственные формы, содержащие липидную фазу |
GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
GB0704846D0 (en) * | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
RU2353349C2 (ru) * | 2007-04-18 | 2009-04-27 | Общество с ограниченной ответственностью "Фармацевтические технологии" | Средство для лечения болезней суставов |
CN101129335B (zh) * | 2007-07-17 | 2010-09-22 | 浙江大学 | 一种纳米结构脂质载体给药系统的用途 |
US8461183B2 (en) | 2008-05-26 | 2013-06-11 | Genfit | PPAR agonist compounds, preparation and uses |
GB201018289D0 (en) * | 2010-10-29 | 2010-12-15 | Biocopea Ltd | Treatment of respiratory disorders |
CN103391767B (zh) * | 2011-02-04 | 2016-08-31 | 第一医疗保健有限公司 | 治疗心血管疾病的组合物和方法 |
WO2012127037A2 (en) * | 2011-03-24 | 2012-09-27 | Leo Pharma A/S | A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative |
CN102793628B (zh) * | 2012-08-23 | 2014-07-02 | 东华大学 | 用于化妆品的液-固混合脂质纳米缓释系统及其制备方法 |
ES2763352T3 (es) * | 2013-01-14 | 2020-05-28 | Infirst Healthcare Ltd | Composiciones de solución sólida y uso en inflamación crónica |
-
2014
- 2014-01-14 ES ES14702460T patent/ES2763352T3/es active Active
- 2014-01-14 KR KR1020237002149A patent/KR20230017914A/ko not_active Application Discontinuation
- 2014-01-14 AU AU2014204737A patent/AU2014204737B2/en active Active
- 2014-01-14 EP EP19188174.7A patent/EP3578172B1/en active Active
- 2014-01-14 BR BR112015015891-9A patent/BR112015015891B1/pt active IP Right Grant
- 2014-01-14 CN CN201480006940.XA patent/CN105007947B/zh active Active
- 2014-01-14 SG SG11201505249VA patent/SG11201505249VA/en unknown
- 2014-01-14 RU RU2015134143A patent/RU2674982C2/ru active IP Right Revival
- 2014-01-14 CA CA2897884A patent/CA2897884C/en active Active
- 2014-01-14 AU AU2014204735A patent/AU2014204735B2/en active Active
- 2014-01-14 SG SG10201704472QA patent/SG10201704472QA/en unknown
- 2014-01-14 EP EP14703279.1A patent/EP2943223B1/en active Active
- 2014-01-14 CN CN201480006216.7A patent/CN104968368B/zh active Active
- 2014-01-14 MX MX2015009105A patent/MX2015009105A/es unknown
- 2014-01-14 KR KR1020157021076A patent/KR102235264B1/ko active IP Right Grant
- 2014-01-14 CA CA2897878A patent/CA2897878A1/en not_active Abandoned
- 2014-01-14 JP JP2015552094A patent/JP6505607B2/ja active Active
- 2014-01-14 KR KR1020157021075A patent/KR20150125648A/ko not_active IP Right Cessation
- 2014-01-14 EP EP21164383.8A patent/EP3858335A1/en active Pending
- 2014-01-14 KR KR1020157021073A patent/KR102252574B1/ko active IP Right Grant
- 2014-01-14 WO PCT/EP2014/050637 patent/WO2014108573A1/en active Application Filing
- 2014-01-14 RU RU2015134142A patent/RU2667977C2/ru active IP Right Revival
- 2014-01-14 MX MX2015009104A patent/MX2015009104A/es active IP Right Grant
- 2014-01-14 CA CA2898000A patent/CA2898000A1/en not_active Abandoned
- 2014-01-14 WO PCT/EP2014/050636 patent/WO2014108572A1/en active Application Filing
- 2014-01-14 NZ NZ709486A patent/NZ709486A/en unknown
- 2014-01-14 EP EP14702460.8A patent/EP2925367B1/en active Active
- 2014-01-14 EP EP20192758.9A patent/EP3795141A1/en active Pending
- 2014-01-14 IL IL282123A patent/IL282123B/en unknown
- 2014-01-14 JP JP2015552095A patent/JP6389190B2/ja active Active
- 2014-01-14 ES ES14703279T patent/ES2830033T3/es active Active
- 2014-01-14 MX MX2015009106A patent/MX2015009106A/es unknown
- 2014-01-14 AU AU2014204734A patent/AU2014204734B2/en active Active
- 2014-01-14 BR BR112015015858-7A patent/BR112015015858B1/pt active IP Right Grant
- 2014-01-14 BR BR112015015898-6A patent/BR112015015898B1/pt active IP Right Grant
- 2014-01-14 SG SG11201505241WA patent/SG11201505241WA/en unknown
- 2014-01-14 KR KR1020217040230A patent/KR102491426B1/ko active IP Right Grant
- 2014-01-14 EP EP14701930.1A patent/EP2943222B1/en active Active
- 2014-01-14 ES ES19188174T patent/ES2875824T3/es active Active
- 2014-01-14 CN CN201480006298.5A patent/CN104981253B/zh active Active
- 2014-01-14 KR KR1020217009229A patent/KR102338569B1/ko active IP Right Grant
- 2014-01-14 CN CN201910070081.5A patent/CN109549927B/zh active Active
- 2014-01-14 SG SG11201505247TA patent/SG11201505247TA/en unknown
- 2014-01-14 IL IL295091A patent/IL295091B2/en unknown
- 2014-01-14 RU RU2015134141A patent/RU2675241C2/ru active IP Right Revival
- 2014-01-14 WO PCT/EP2014/050638 patent/WO2014108574A1/en active Application Filing
- 2014-01-14 JP JP2015552096A patent/JP6378694B2/ja active Active
- 2014-01-14 ES ES14701930T patent/ES2829904T3/es active Active
-
2015
- 2015-07-13 ZA ZA2015/05002A patent/ZA201505002B/en unknown
- 2015-07-13 ZA ZA2015/05003A patent/ZA201505003B/en unknown
- 2015-07-13 ZA ZA2015/05004A patent/ZA201505004B/en unknown
- 2015-07-14 IL IL239922A patent/IL239922B/en active IP Right Grant
- 2015-07-14 IL IL239923A patent/IL239923A0/en unknown
- 2015-07-14 IL IL239924A patent/IL239924A0/en unknown
-
2016
- 2016-04-07 HK HK16103939.0A patent/HK1216004A1/zh unknown
- 2016-05-18 HK HK16105729.9A patent/HK1217899A1/zh unknown
- 2016-05-18 HK HK16105732.4A patent/HK1217651A1/zh unknown
- 2016-11-11 AU AU2016256804A patent/AU2016256804B2/en active Active
-
2019
- 2019-03-27 JP JP2019061720A patent/JP2019116498A/ja active Pending
-
2021
- 2021-08-27 JP JP2021139210A patent/JP7250865B2/ja active Active
-
2023
- 2023-03-22 JP JP2023045431A patent/JP2023078365A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016508155A5 (ja) | ||
JP2016504403A5 (ja) | ||
JP2016505625A5 (ja) | ||
RU2015134141A (ru) | Композиции твердых растворов и их применение при хроническом воспалении | |
AR122743A2 (es) | Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek | |
HRP20201043T1 (hr) | Spojevi 4-amino-imidazokinolina | |
DOP2016000175A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR084639A1 (es) | Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo | |
HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
AR106652A1 (es) | Compuestos para tratar la esclerosis lateral amiotrófica | |
DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
DOP2014000016A (es) | Indazoles novedosos inhibidores de janus quinasa | |
HN2012001037A (es) | Derivados del acido carbamoil-metil-amino-acetico sustiituido como inhibidores de nep novedosos | |
JP2016506941A5 (ja) | ||
AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
UY32490A (es) | Inhibidores de beta-secretasa | |
CO6690768A2 (es) | Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7 | |
CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
CU24355B1 (es) | Derivados de 2((( oxadiazol/triazol/tetrazol/isoxazol) metil) fenil)-1-(heterociclil)-ona como inhibidores activos de autotaxina | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
HRP20190900T1 (hr) | Trifluorometil alkoholi kao modulatori ror-gama-t | |
RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
JP2014509655A5 (ja) |